Panacea Biotec has announced significant developments in its vaccine business. The company has received an order worth ₹127.20 crore from the Central Medical Services Society (CMSS), Ministry of Health and Family Welfare, Government of India, for the supply of bivalent oral polio vaccine (bOPV).

Order Details

Key Points

• The company received the Letter of Acceptance (LOA) from CMSS on October 8.
• The vaccine supply will be completed in several tranches over a period ranging from 90 to 480 days from the date of issuance of the LOA.
• This order is not classified as a related party transaction and does not involve any interest from the promoter/promoter group or group companies.

Additional Developments

• UNICEF has awarded Panacea Biotec a long-term agreement worth approximately $35.65 million (₹315.00 crore) for supplying polio vaccines.
• The UNICEF agreement covers the period from April 2026 to March 2030.
• Orders for Q2 CY2026 and CY2027 are to be executed by CY2027.

Significance

These substantial orders underscore Panacea Biotec's strong position in the vaccine manufacturing sector, particularly in the production of polio vaccines. The contracts with a government entity like CMSS and an international organization like UNICEF highlight the company's role in supporting both national and global health initiatives, specifically in the ongoing efforts to maintain polio eradication.

Market Implications

For investors and market watchers, these developments signal potential positive implications for Panacea Biotec's revenue stream in the coming years. The domestic order's size and the extended delivery timeline, coupled with the long-term UNICEF agreement, suggest a steady inflow of revenue, which could contribute significantly to the company's financial performance.

Market Response

Following the announcement, Panacea Biotec's shares traded marginally higher at ₹432.05, indicating a positive market sentiment towards these developments.

Conclusion

The ₹127.20 crore domestic order for bOPV supply and the $35.65 million UNICEF agreement represent significant business opportunities for Panacea Biotec. These developments not only reinforce the company's capabilities in vaccine production but also its important role in public health initiatives both domestically and internationally. Stakeholders will likely be keeping a close eye on how these orders impact the company's financial results in the upcoming quarters and years.

Panacea Biotec , a prominent player in the pharmaceutical industry, has announced a significant development in its business operations. The company has secured a substantial order worth approximately ₹315.00 crore (US$ 35.65 million) from the United Nations International Children's Emergency Fund (UNICEF) for the supply of bivalent oral polio vaccine (bOPV).

Key Details of the Order

Contract Specifics

Panacea Biotec received a Letter of Award from UNICEF for a Long-Term Agreement to supply bOPV. This agreement spans from April 1, 2026, to March 31, 2030. The current order value of ₹315.00 crore specifically covers the supply for Q2 CY2026 and CY2027.

The company will be supplying the bOPV in both 10 and 20 vial presentations, catering to UNICEF's requirements. The vaccine will be used for UNICEF's global polio eradication efforts.

Transparency in Award Process

As part of UNICEF's commitment to transparency, the organization will make the award public by publishing the following information on its website:

1. Supplier's name (Panacea Biotec Limited)
2. Vaccine type (bOPV)
3. Duration of the award
4. Total award value
5. Awarded prices per supplier, product presentation, and year

Impact on Panacea Biotec

This order represents a significant business opportunity for Panacea Biotec, potentially strengthening its position in the global vaccine market. The company's ability to secure such a substantial international order from a prestigious organization like UNICEF underscores its capabilities in vaccine production and quality standards.

Regulatory Compliance

Panacea Biotec has duly informed the stock exchanges about this development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that this order does not fall under related party transactions, and there is no interest of promoters or group companies in UNICEF.

This order comes as positive news for Panacea Biotec, potentially boosting investor confidence and highlighting the company's role in global health initiatives, particularly in the fight against polio.